尤瑞克林用于急性脑梗死的抗炎效果及安全性  

Anti-inflammatory Effects and Safety of Urinary Kallidinogenase in Treatment of Acute Cerebral Infarction

作　　者：王彬[1] 张凤云[2] 耿峰 杨淑芹[1] 张本卓[2] 

机构地区：[1]牡丹江医学院第二附属医院药剂科,黑龙江牡丹江157015 [2]牡丹江医学院第二附属医院神经内科,黑龙江牡丹江157015

出　　处：《中国医院用药评价与分析》2017年第9期1183-1185,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：牡丹江医学院科学技术研究项目(No.ZS201522)

摘　　要：目的:观察尤瑞克林治疗急性脑梗死的临床疗效,探讨其抗炎效果及安全性。方法:将2016年牡丹江医学院第二附属医院收治的急性脑梗死患者108例以随机数字表法分为对照组和观察组,每组54例。在常规治疗基础上,对照组患者给予注射用血塞通,观察组患者给予注射用尤瑞克林,均连续治疗14 d。比较两组患者治疗前后的美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS)评分、超敏C反应蛋白(hs-CRP)水平。结果:治疗前,两组患者的NIHSS评分、hs-CRP水平的差异均无统计学意义(P>0.05);治疗后,两组患者NIHSS评分、hs-CRP水平均较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。观察组患者的总有效率为98.14%(53/54),明显高于对照组的77.78%(42/54),差异有统计学意义(P<0.05)。两组患者均未发生严重不良反应。结论:尤瑞克林治疗急性脑梗死的疗效显著,能明显降低患者血清hs-CRP水平,有利于减轻炎症反应,且不良反应较少。OBJECTIVE： To observe the clinical efficacy of urinary kallidinogenase in treatment of acute cerebral infarction,and to probe into the anti-inflammatory effects and safety. METHDS： 108 patients with acute cerebral infarction admitted into the Second Affiliated Hospital of Mudanjiang Medical College were extracted to be divided into observation group and control group via the random number table,with 54 cases in each. Based on the conventional treatment, the control group was given Xuesaitong injections, while the observation group received urinary kallidinogenase injections,the treatment course last for 14 d. The national institutes of health stroke scale（ NIHSS）,hs-CRP level of two groups were compared before and after treatment. RESULTS： Before treatment,there was no statistically significant difference between two groups in the NIHSS score and hs-CRP level（ P〈0. 05）. After treatment,the NIHSS score and hs-CRP level decreased significantly compared with before treatment,and the observation group was lower than the control group,with statistically significant difference（ P〈0. 05）. The total effective rate of observation group was 98. 14%（ 53/54）,significantly higher than that of control group 77. 78%（ 42/54）,with statistically significant difference（ P〈0. 05）. There was no severe adverse drug reactions in both groups.CONCLUSIONS： The efficacy of urinary kallidinogenase in treatment of acute cerebral infarction is remarkable,which can significantly reduce the serum hs-CRP level and relieve inflammation of patients with few adverse drug reactions.

关 键 词：尤瑞克林 急性脑梗死 超敏C反应蛋白 注射用血塞通 

分 类 号：R972[医药卫生—药品]